I would assume if a psychedelic gets approved from a major regulatory authority (e.g., FDA, EMEA, etc) for an indication, that would resolve as "yes"?

Not necessarily. If it's just a psychological benefit, even as extreme as making peace with death, that's still individual and subjective, right?

I mean no regulatory authority is going to approve that as an indication since that’s not a disease

Treatment of any well-defined and generally recognized medical condition would count. Treatments already known, such as cannabis for glaucoma and nausea, or psilocybin for cluster headaches, would not count.

@Quroe

Market resolves in or about 30 days, by consensus.

can you say more about the resolution? what consensus?

@Slackhammer bump^